EMERYVILLE, Calif., Feb. 27,
2024 /PRNewswire/ -- Dynavax Technologies Corporation
(Nasdaq: DVAX), a commercial-stage biopharmaceutical company
developing and commercializing innovative vaccines, today
announced that the Company will present at TD Cowen's 44th Annual
Health Care Conference on Monday, March
4 at 10:30 a.m. ET.
The presentation will be webcast and may be accessed through the
"Events & Presentations" page on the "Investors" section of the
Company's website at
https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company
developing and commercializing innovative vaccines to help protect
the world against infectious diseases. The Company has two
commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine
(Recombinant), Adjuvanted], which is approved in the U.S., the
European Union and Great Britain
for the prevention of infection caused by all known subtypes of
hepatitis B virus in adults 18 years of age and older, and CpG
1018® adjuvant, currently used in multiple adjuvanted COVID-19
vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier
vaccine adjuvant with adjuvanted vaccine clinical programs for
shingles and Tdap, and through global collaborations, currently
focused on adjuvanted vaccines for COVID-19, plague, seasonal
influenza and universal influenza. For more information about our
marketed products and development pipeline, visit www.dynavax.com
and follow Dynavax on LinkedIn and Twitter.
For Investors/Media:
Paul
Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-td-cowens-44th-annual-health-care-conference-302073426.html
SOURCE Dynavax Technologies